Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
复制标题
DOI：
10.1158/1535-7163.mct-21-0950
复制
发表时间：
2022-06-01
影响因子：
5.7
通讯作者：
Subbiah V
中科院分区：
文献类型：
--
作者：
Adashek JJ;Menta AK;Reddy NK;Desai AP;Roszik J;Subbiah V
BRAF 加 MEK 抑制剂组合目前已获得 FDA 批准用于治疗黑色素瘤、非小细胞肺癌和未分化甲状腺癌。 BRAF 抑制在 BRAF V600 突变结直肠癌中缺乏临床益处，阻碍了其与组织无关的药物开发。我们回顾了 AACR GENIE 数据库，了解不同肿瘤类型中 BRAF V600 突变的流行情况。我们回顾了有关临床反应病例报告的文献、接受 BRAF 抑制剂治疗的 BRAF V600 突变阳性非黑色素瘤恶性肿瘤患者的结果，以及已发表的成人和儿童试验的数据。 BRAF V600 突变在多种非黑色素瘤恶性肿瘤（> 40 种不同的肿瘤类型）中普遍存在，导致癌基因成瘾，并且在广泛的成人和儿童非黑色素瘤罕见恶性肿瘤中具有临床作用。除了目前 BRAF 加 MEK 批准的癌症之外，还需要继续进行与组织无关的药物开发。
BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation—positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malignancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.
影响因子：
1.1
作者：
Stempel, Jessica M;Bustamante Alvarez, Jean G;Carpio, Andres Mora;Mittal, Varun;Dourado, Claudia
通讯作者：
Dourado, Claudia
影响因子：
0.8
作者：
Ali SM;He J;Carson W;Stephens PJ;Fiorillo J;Lipson D;Palmer GA;Ross JS;Miller VA;Sharman J
通讯作者：
Sharman J